10.2.2012 Official Journal of the European Union L 37/65 COMMISSION DIRECTIVE 2012/3/EU of 9 February 2012 amending Directive 98/8/EC of the European Parliament and of the Council to include bendiocarb as an active substance in Annex I thereto (Text with EEA relevance) THE EUROPEAN COMMISSION, Having regard to the Treaty on the Functioning of the European Union, Having regard to Directive 98/8/EC of the European Parliament and of the Council of 16 February 1998 concerning the placing of biocidal products on the market (!), and in particular the second subparagraph of Article 16(2) thereof, Whereas: 1 Commission Regulation (EC) No 1451/2007 of 4 December 2007 on the second phase of the 10-year work programme referred to in Article 16(2) of Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market (%) establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I, IA or IB to Directive 98/8/EC. That list includes bendiocarb. Pursuant to Regulation (EC) No 1451/2007, bendiocarb has been evaluated in accordance with Article 11(2) of Directive 98/8/EC for use in product type 18, insec- ticides, acaricides and products to control other arth- ropods, as defined in Annex V to that Directive. The United Kingdom was designated as rapporteur Member State and submitted the competent authority report, together with a recommendation, to the Commission on 1 April 2008 in accordance with Article 14(4) and (6) of Regulation (EC) No 1451/2007. The competent authority report was reviewed by the Member States and the Commission. In accordance with Article 15(4) of Regulation (EC) No 1451/2007, the findings of the review were incorporated, within the Standing Committee on Biocidal Products on 22 September 2011, in an assessment report. It appears from the evaluations that biocidal products used as insecticides, acaricides and products to control other arthropods and containing bendiocarb may be L 123, 24.4.1998, p. 1. L 325, 11.12.2007, p. 3. (10) expected to satisfy the requirements laid down in Article 5 of Directive 98/8/EC. It is therefore appropriate to include bendiocarb in Annex I to that Directive. Not all potential uses have been evaluated at Union level. For example, the assessment only considers professional use, and does not cover direct application to soil or application on food or feedstuff or on surfaces that will come in contact with food or feedstuff. It is therefore appropriate that Member States assess those uses or exposure scenarios and those risks to human populations and to environmental compartments that have not been representatively addressed in the Union level risk assessment and, when granting product auth- orisations, ensure that appropriate measures are taken or specific conditions imposed in order to reduce the identified risks to acceptable levels. In view of the risks identified for the aquatic environment due to wet cleaning of treated surfaces, resulting in emissions of a certain scale to surface waters, it is appropriate to require that products not be authorised for use on surfaces that are prone to frequent wet cleaning, other than crack and crevice or spot treat- ments, unless data are submitted demonstrating that the product will meet the requirements of both Article 5 of and Annex VI to Directive 98/8/EC, if necessary by the application of appropriate risk mitigation measures. In view of the risks identified for human health, it is appropriate to require that products authorised for industrial or professional use must be used with appro- priate personal protective equipment, unless it can be demonstrated in the application for product authori- sation that risks to industrial or professional users can be reduced to an acceptable level by other means. In view of the potential risk to honey bees, it is appro- priate to require that, where relevant, action is taken to prevent foraging bees gaining access to treated nests by removing the combs or blocking the nest entrances. The provisions of this Directive should be applied at the same time in all Member States in order to ensure equal treatment on the Union market of biocidal products containing the active substance bendiocarb and also to facilitate the proper operation of the biocidal products market in general.